Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 355

1.

A Fluorescence-Based High-Throughput Assay for the Identification of Anticancer Reagents Targeting Fructose-1,6-Bisphosphate Aldolase.

Cho EJ, Devkota AK, Stancu G, Edupunganti R, Powis G, Dalby KN.

SLAS Discov. 2018 Jan;23(1):1-10. doi: 10.1177/2472555217726325. Epub 2017 Aug 18.

PMID:
28820953
2.

Modeling of Patient-Derived Xenografts in Colorectal Cancer.

Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S.

Mol Cancer Ther. 2017 Jul;16(7):1435-1442. doi: 10.1158/1535-7163.MCT-16-0721. Epub 2017 May 3.

3.

Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer.

Chang HR, Nam S, Lee J, Kim JH, Jung HR, Park HS, Park S, Ahn YZ, Huh I, Balch C, Ku JL, Powis G, Park T, Jeong JH, Kim YH.

Oncotarget. 2016 Dec 6;7(49):81435-81451. doi: 10.18632/oncotarget.12963.

4.

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.

Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, Kwong LN, Kopetz S.

Oncotarget. 2016 Jun 28;7(26):39595-39608. doi: 10.18632/oncotarget.9153.

5.

Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1α Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target.

Grandjean G, de Jong PR, James B, Koh MY, Lemos R, Kingston J, Aleshin A, Bankston LA, Miller CP, Cho EJ, Edupuganti R, Devkota A, Stancu G, Liddington RC, Dalby K, Powis G.

Cancer Res. 2016 Jul 15;76(14):4259-4269. doi: 10.1158/0008-5472.CAN-16-0401. Epub 2016 Jun 3.

6.

ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation.

de Jong PR, Taniguchi K, Harris AR, Bertin S, Takahashi N, Duong J, Campos AD, Powis G, Corr M, Karin M, Raz E.

Nat Commun. 2016 May 17;7:11551. doi: 10.1038/ncomms11551.

7.

Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.

Kirkpatrick DL, Powis G.

Antioxid Redox Signal. 2017 Feb 20;26(6):262-273. doi: 10.1089/ars.2016.6633. Epub 2016 Apr 22. Review.

8.

Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.

Chang HR, Park HS, Ahn YZ, Nam S, Jung HR, Park S, Lee SJ, Balch C, Powis G, Ku JL, Kim YH.

BMC Cancer. 2016 Mar 9;16:200. doi: 10.1186/s12885-016-2232-2.

9.

A new HIF-1α/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice.

Koh MY, Gagea M, Sargis T, Lemos R Jr, Grandjean G, Charbono A, Bekiaris V, Sedy J, Kiriakova G, Liu X, Roberts LR, Ware C, Powis G.

Hepatology. 2016 May;63(5):1576-91. doi: 10.1002/hep.28468. Epub 2016 Mar 7.

10.

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L.

J Clin Oncol. 2015 Dec 1;33(34):4032-8. doi: 10.1200/JCO.2015.63.2497. Epub 2015 Oct 12.

11.

A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.

Nam S, Chang HR, Jung HR, Gim Y, Kim NY, Grailhe R, Seo HR, Park HS, Balch C, Lee J, Park I, Jung SY, Jeong KC, Powis G, Liang H, Lee ES, Ro J, Kim YH.

Cancer Lett. 2015 Jan 28;356(2 Pt B):880-90. doi: 10.1016/j.canlet.2014.10.038. Epub 2014 Nov 4.

12.

Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.

Koh MY, Nguyen V, Lemos R Jr, Darnay BG, Kiriakova G, Abdelmelek M, Ho TH, Karam J, Monzon FA, Jonasch E, Powis G.

Cancer Res. 2015 Jan 15;75(2):316-29. doi: 10.1158/0008-5472.CAN-13-2190. Epub 2014 Nov 24.

13.

HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer.

Chang HR, Nam S, Kook MC, Kim KT, Liu X, Yao H, Jung HR, Lemos R Jr, Seo HH, Park HS, Gim Y, Hong D, Huh I, Kim YW, Tan D, Liu CG, Powis G, Park T, Liang H, Kim YH.

Gut. 2016 Jan;65(1):19-32. doi: 10.1136/gutjnl-2014-307918. Epub 2014 Nov 19.

14.

The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression.

Kim JM, Jeung HC, Rha SY, Yu EJ, Kim TS, Shin YK, Zhang X, Park KH, Park SW, Chung HC, Powis G.

Mol Cancer Ther. 2014 Dec;13(12):3074-85. doi: 10.1158/1535-7163.MCT-13-1001. Epub 2014 Oct 24.

15.

PATHOME: an algorithm for accurately detecting differentially expressed subpathways.

Nam S, Chang HR, Kim KT, Kook MC, Hong D, Kwon CH, Jung HR, Park HS, Powis G, Liang H, Park T, Kim YH.

Oncogene. 2014 Oct 9;33(41):4941-51. doi: 10.1038/onc.2014.80. Epub 2014 Mar 31.

16.

FXR silencing in human colon cancer by DNA methylation and KRAS signaling.

Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, Izzo J, He N, Wei C, Baladandayuthapani V, Liang H, Kopetz S, Powis G, Guo GL.

Am J Physiol Gastrointest Liver Physiol. 2014 Jan 1;306(1):G48-58. doi: 10.1152/ajpgi.00234.2013. Epub 2013 Oct 31. Erratum in: Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G357.

17.

Improved synthesis of 17β-hydroxy-16α-iodo-wortmannin, 17β-hydroxy-16α-iodoPX866, and the [(131)I] analogue as useful PET tracers for PI3-kinase.

Sun D, Bhanu Prasad BA, Schuber PT Jr, Peng Z, Maxwell DS, Martin DV, Guo L, Han D, Kurihara H, Yang DJ, Gelovani JG, Powis G, Bornmann WG.

Bioorg Med Chem. 2013 Sep 1;21(17):5182-7. doi: 10.1016/j.bmc.2013.06.036. Epub 2013 Jun 27.

18.

Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer.

Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ, Von Hoff D, Hingorani SR, Palculict TB, Izzo J, Kiriakova GM, Abdelmelek M, Bartholomeusz G, James BP, Powis G.

Cancer Res. 2013 Jun 1;73(11):3235-47. doi: 10.1158/0008-5472.CAN-11-1433. Epub 2013 Apr 30.

19.

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S.

Clin Cancer Res. 2013 Feb 1;19(3):657-67. doi: 10.1158/1078-0432.CCR-11-1446. Epub 2012 Dec 18.

20.

The promise of patient-derived xenografts: the best laid plans of mice and men.

Kopetz S, Lemos R, Powis G.

Clin Cancer Res. 2012 Oct 1;18(19):5160-2. doi: 10.1158/1078-0432.CCR-12-2408. Epub 2012 Aug 21.

21.

Passing the baton: the HIF switch.

Koh MY, Powis G.

Trends Biochem Sci. 2012 Sep;37(9):364-72. doi: 10.1016/j.tibs.2012.06.004. Epub 2012 Jul 18. Review.

22.

Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium.

Guntle GP, Jagadish B, Mash EA, Powis G, Dorr RT, Raghunand N.

Transl Oncol. 2012 Jun;5(3):190-9. Epub 2012 Jun 1.

23.

AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer.

Kim YH, Liang H, Liu X, Lee JS, Cho JY, Cheong JH, Kim H, Li M, Downey TJ, Dyer MD, Sun Y, Sun J, Beasley EM, Chung HC, Noh SH, Weinstein JN, Liu CG, Powis G.

Cancer Res. 2012 May 15;72(10):2512-21. doi: 10.1158/0008-5472.CAN-11-3870. Epub 2012 Mar 20.

24.

Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells.

Sheveleva EV, Landowski TH, Samulitis BK, Bartholomeusz G, Powis G, Dorr RT.

Mol Cancer Res. 2012 Mar;10(3):392-400. doi: 10.1158/1541-7786.MCR-11-0359. Epub 2012 Jan 24.

25.

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G.

J Natl Cancer Inst. 2012 Feb 8;104(3):228-39. doi: 10.1093/jnci/djr523. Epub 2012 Jan 13.

26.

Radiation Resistance in Cancer Therapy: meeting summary and research opportunities. Report of an NCI Workshop held September 1-3, 2010.

Glazer PM, Grandis J, Powell SN, Brown JM, Helleday T, Bristow R, Powis G, Hill RP, Le QT, Pelroy R, Mohla S, Bernhard EJ; NCI Workshop Participants.

Radiat Res. 2011 Sep;176(3):e0016-21. Epub 2011 Jul 8. No abstract available.

PMID:
21867428
27.

Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities: Report of an NCI Workshop held September 1-3, 2010.

Glazer PM, Grandis J, Powell SN, Brown JM, Helleday T, Bristow R, Powis G, Hill RP, Le QT, Pelroy R, Mohla S, Bernhard EJ.

Radiat Res. 2011 Jul 8. [Epub ahead of print] No abstract available.

PMID:
21740251
28.

The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion.

Koh MY, Lemos R Jr, Liu X, Powis G.

Cancer Res. 2011 Jun 1;71(11):4015-27. doi: 10.1158/0008-5472.CAN-10-4142. Epub 2011 Apr 21.

29.

Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.

Kim YW, Liu TJ, Koul D, Tiao N, Feroze AH, Wang J, Powis G, Yung WK.

Neuro Oncol. 2011 Apr;13(4):367-75. doi: 10.1093/neuonc/nor012.

30.

HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance.

Schwartz DL, Bankson J, Bidaut L, He Y, Williams R, Lemos R, Thitai AK, Oh J, Volgin A, Soghomonyan S, Yeh HH, Nishii R, Mukhopadhay U, Alauddin M, Mushkudiani I, Kuno N, Krishnan S, Bornman W, Lai SY, Powis G, Hazle J, Gelovani J.

Mol Cancer Res. 2011 Mar;9(3):259-70. doi: 10.1158/1541-7786.MCR-10-0469. Epub 2011 Mar 1.

31.

Development of sulfonamide AKT PH domain inhibitors.

Ahad AM, Zuohe S, Du-Cuny L, Moses SA, Zhou LL, Zhang S, Powis G, Meuillet EJ, Mash EA.

Bioorg Med Chem. 2011 Mar 15;19(6):2046-54. doi: 10.1016/j.bmc.2011.01.049. Epub 2011 Feb 1.

32.

PI-3-Kinase inhibitors in colorectal cancer.

Ihle NT, Powis G, Kopetz S.

Curr Cancer Drug Targets. 2011 Feb;11(2):190-8. Review.

PMID:
21158718
33.

Recent development of anticancer therapeutics targeting Akt.

Morrow JK, Du-Cuny L, Chen L, Meuillet EJ, Mash EA, Powis G, Zhang S.

Recent Pat Anticancer Drug Discov. 2011 Jan;6(1):146-59. Review.

34.

Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase.

Kim YH, Coon A, Baker AF, Powis G.

Cancer Chemother Pharmacol. 2011 Aug;68(2):405-13. doi: 10.1007/s00280-010-1500-0. Epub 2010 Nov 11.

35.

Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.

Schwartz DL, Bankson JA, Lemos R Jr, Lai SY, Thittai AK, He Y, Hostetter G, Demeure MJ, Von Hoff DD, Powis G.

Mol Cancer Ther. 2010 Jul;9(7):2057-67. doi: 10.1158/1535-7163.MCT-09-0768. Epub 2010 Jun 29.

36.

IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes.

Poindexter NJ, Williams RR, Powis G, Jen E, Caudle AS, Chada S, Grimm EA.

Exp Dermatol. 2010 Aug;19(8):714-22. doi: 10.1111/j.1600-0625.2010.01077.x.

37.

Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice.

Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS, Herbst RS.

J Thorac Oncol. 2010 Jul;5(7):940-9. doi: 10.1097/JTO.0b013e3181dc211f.

38.

Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.

Gwak HS, Shingu T, Chumbalkar V, Hwang YH, DeJournett R, Latha K, Koul D, Alfred Yung WK, Powis G, Farrell NP, Bögler O.

Int J Cancer. 2011 Feb 15;128(4):787-96. doi: 10.1002/ijc.25394.

39.

Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.

Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G.

Mol Cancer Ther. 2010 Mar;9(3):706-17. doi: 10.1158/1535-7163.MCT-09-0985. Epub 2010 Mar 2.

40.

Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.

Ihle NT, Powis G.

Mol Aspects Med. 2010 Apr;31(2):135-44. doi: 10.1016/j.mam.2010.02.003. Epub 2010 Feb 20. Review.

41.

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.

Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK.

Neuro Oncol. 2010 Jun;12(6):559-69. doi: 10.1093/neuonc/nop058. Epub 2010 Feb 15.

42.

In Vivo Therapeutic Silencing of Hypoxia-Inducible Factor 1 Alpha (HIF-1α) Using Single-Walled Carbon Nanotubes Noncovalently Coated with siRNA.

Bartholomeusz G, Cherukuri P, Kingston J, Cognet L, Lemos R, Leeuw TK, Gumbiner-Russo L, Weisman RB, Powis G.

Nano Res. 2009 Apr 17;2(4):279-291.

43.

The biological effects of isoform-specific PI3-kinase inhibition.

Ihle NT, Powis G.

Curr Opin Drug Discov Devel. 2010 Jan;13(1):41-9. Review.

PMID:
20047145
44.

HIF-1alpha and cancer therapy.

Koh MY, Spivak-Kroizman TR, Powis G.

Recent Results Cancer Res. 2010;180:15-34. doi: 10.1007/978-3-540-78281-0_3. Review.

PMID:
20033376
45.

Inhibiting the hypoxia response for cancer therapy: the new kid on the block.

Koh MY, Spivak-Kroizman TR, Powis G.

Clin Cancer Res. 2009 Oct 1;15(19):5945-6. doi: 10.1158/1078-0432.CCR-09-1650. Epub 2009 Sep 29.

46.

Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.

Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.

Bioorg Med Chem. 2009 Oct 1;17(19):6983-92. doi: 10.1016/j.bmc.2009.08.022. Epub 2009 Aug 19.

47.

In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.

Moses SA, Ali MA, Zuohe S, Du-Cuny L, Zhou LL, Lemos R, Ihle N, Skillman AG, Zhang S, Mash EA, Powis G, Meuillet EJ.

Cancer Res. 2009 Jun 15;69(12):5073-81. doi: 10.1158/0008-5472.CAN-08-3839. Epub 2009 Jun 2.

48.

HAF : the new player in oxygen-independent HIF-1alpha degradation.

Koh MY, Powis G.

Cell Cycle. 2009 May 1;8(9):1359-66. Review.

49.

The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects.

Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J, Williams R, Lemos R, Oh J, Volgin A, Soghomonyan S, Nishii R, Alauddin M, Mukhopadhay U, Peng Z, Bornmann W, Gelovani J.

Mol Cancer Ther. 2009 Apr;8(4):947-58. doi: 10.1158/1535-7163.MCT-08-0981.

50.

Inhibiting PI-3-K for glioma therapy.

Powis G, Ihle NT, Yung WK.

Cell Cycle. 2009 Feb 1;8(3):335. Epub 2009 Feb 1. No abstract available.

PMID:
19164951

Supplemental Content

Support Center